Stock Ratings / Health Care / RDY / forecast

ELAN (45) BMRN (74) SMMT (40) SYRE (55) ⌘ Pro Terminal →

Dr. Reddy's Laboratories Ltd (RDY) 12-Month Stock Forecast & Price Target Cone

$14.17 +0.43% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.15

Dr. Reddy's Laboratories Ltd (RDY) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $11.83B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RDY Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RDY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Dr. Reddy's Laboratories Ltd (NYSE: RDY) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $14.17 (+0.43% 1D, market cap $11.83B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, RDY ranks #127 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RDY compare to ELAN and BMRN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RDY carries a Roarable C (64/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, ELAN (Elanco Animal Health Incorporated) holds a D grade (45/100 RQD, P/E N/A, ROIC -2.5%, cap $11.52B) and BMRN (BioMarin Pharmaceutical Inc.) posts a B grade (74/100 RQD, P/E 31.9x, ROIC 6.0%, cap $11.33B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while RDY leads on capital efficiency (9.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RDY?

▼

For Dr. Reddy's Laboratories Ltd (RDY), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #127 in Health Care, while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $14.15 (-0.11%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 6.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RDY)Realized 20D OHLCV Swing Band: ±3.6%

Deterministic 5-Pillar Attribution (64/100 Composite)

🔍 WHY RDY SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (25% of score)

Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Whale & Options Positioning+13/20 pts (20% of score)

20D Institutional Volume Accumulation (±3.6% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality11/20 pts (-9 pt drag)

Capital intensity & 13.9% operating margin leave 9 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$12.75+3.5% Next Q

Q2 (-2Q)

Grade C$13.19+7.3% Next Q

Q3 (-1Q)

Grade C$14.15+0.1% Next Q

Current

Grade C$14.17+1.1% Hist 90D α

Trajectory: C (56) → C (64)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the RDY Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 64/100 (C) score, RDY faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($12.65) or 200D SMA ($13.23) invalidates the momentum regime and cuts Target Base ($14.55) toward Bear Floor ($11.35).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RDY• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RDY Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 64%NO 36%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your RDY Position Size: $10,000

Shares at $14.17: 705.7 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $11.35

$8,010

$-1,990 (-19.9%)

12M Consensus BaseTarget $14.55

$10,268

+$268 (+2.7%)

12M Bull Case BreakoutTarget $17.17

$12,117

+$2,117 (+21.2%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$15	74%	A
Goldman SachsSector Coverage Lead	BUY	$16	69%	B
JP MorganUS Large-Cap Research	HOLD	$13	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (RDY Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RDY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +6.14%⚡ TESTING RESISTANCE

2026-11-03O $14.11H $14.17L $14.11C $14.17VOL 1.83M

RES: $14.27SUP: $11.65SMA50: $12.65SMA200: $13.23

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RDY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RDY Butterfly Map → + Track RDY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.3%/yr Implied 5Y Growth

vs. +6.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RDY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RDY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RDY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RDY)

Health Care Rank #127 of 1016 ⚔️ ELAN vs RDY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RDY vs. ELAN, BMRN, SMMT, SYRE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Dr. Reddy's Laboratories Ltd (RDY) ranks #127 by composite RQD confidence (64/100, grade C) and #93 by equity capitalization ($11.83B). Within this direct 5-issuer industry benchmark cohort, BMRN leads on earnings valuation at 31.9x trailing P/E, while RDY leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. BMRN currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with RDY at 64/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RDY ACTIVE Dr. Reddy's Laboratories Ltd	C	64/100	32.8x	—	9.9%	+0.43%	$11.83B	Benchmark Subject
ELAN Elanco Animal Health Incorporated	D	45/100	—	55.0%	-2.5%	-0.77%	$11.52B	/elan-vs-rdy →
BMRN BioMarin Pharmaceutical Inc.	B	74/100	31.9x	77.7%	6.0%	+1.77%	$11.33B	/bmrn-vs-rdy →
SMMT Summit Therapeutics Inc.	D-	40/100	—	—	-35.0%	-1.05%	$12.82B	/smmt-vs-rdy →
SYRE Spyre Therapeutics Inc.	D+	55/100	—	—	-20.0%	-2.42%	$10.08B	/syre-vs-rdy →

2. RDY Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Dr. Reddy's Laboratories Ltd (RDY) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $11.83B, trailing P/E of 32.8x, forward P/E of 30.5x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.

3. RDY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RDY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does RDY compare to ELAN and BMRN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for RDY?

Where is RDY trading relative to its 50-day, 200-day, and 52-week technical levels?

RDY last traded at $14.17 (+0.43% on volume of 1,826,451 shares), positioning the stock +12.02% above its 50-day simple moving average ($12.65) and +7.11% above its 200-day simple moving average ($13.23). Across its 52-week range of $11.36 to $15.67, RDY sits at the 65.2% percentile with a 14-day RSI of 76.2 (OVERBOUGHT (>70)) and an implied next-earnings move of ±3.6% ($13.66 to $14.68).

RDY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is RDY's 12-month stock price target?

Dr. Reddy's Laboratories Ltd (RDY) carries a 12-month consensus base price target of $14.55 (+2.7% from $14.17), with a bull-case target of $17.17 and a bear-case floor of $11.35.

Is RDY stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates RDY C (Hold — HOLD) with an RQD Confidence score of 64/100.

Direct Sub-Reports: RDY RQD Cockpit RDY 12M Forecast RDY Earnings & Move RDY Dividends & DRIP RDY Insiders & 13F RDY Whale Options RDY Profit Sankey RDY News & Why

ROARABLE RATING BRIEF • RQD 64/100 (C) ✓ STAGE-C NUMBER FIREWALL VERIFIED

RDY — Dr. Reddy's Laboratories Ltd: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:10:15Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, RDY scores 64 out of 100, grade C, labeled "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

Fundamental Cash Engine: 11 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 9.9% and FCF yield of 2.21%. The FCF yield is modest relative to a 30.5x forward P/E, which implies the market is pricing in growth that the current cash generation does not yet support.
Whale 13F Flow: 13 / 20. Per the Roarable RQD rating, this reflects institutional accumulation and options positioning. The score is moderate, indicating neither strong conviction nor clear distribution in the source data.
Insider Conviction: 12 / 20. Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The moderate score suggests insider activity is neither a strong tailwind nor a warning sign.
Macro Regime Fit: 12 / 20. Per the Roarable RQD rating, beta is 1.05 with sector sensitivity noted. RDY roughly tracks broad market volatility, so it is unlikely to cushion a risk-off move nor to dramatically outperform in a rally.
Forensic Balance Sheet: 16 / 20. Per the Roarable RQD rating, the Altman Z is 3.74, Piotroski F is 8/9, and Debt/Equity is 0.39. This is the strongest pillar and points to a financially sound balance sheet.

For a prospective investor, the upside case rests on balance sheet quality and the market's tolerance for a premium multiple. The valuation tradeoff is that a trailing P/E of 32.8 and EV/EBITDA of 21 leave limited margin for error if growth or margins disappoint. The rating's "Hold" label reflects that balance-sheet strength is offset by weak cash-return metrics and a demanding valuation.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
14.11	$11.78B	32.8	30.5	21	0.43	0%	1.05	$11.36 - $15.67	9.9%

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, six items were published between roughly 1 and 15 hours before the data timestamp:

Earnings-related coverage: Items reference "2027 Q2 - Results - Earnings Call Presentation" dated 2026-10-23 and a "Q2 Earnings Call Highlights" piece. These point to a recently reported quarter, but the figures themselves are not provided.
Price action: Two items describe share moves, one reporting a 4.1% surge (flagged GREEN, CATALYST) and one a 4.8% jump "After Strong Earnings" (flagged GREEN, CATALYST). Market data shows the stock at $14.11, down 0.28% on the day.
Options and positioning: A Moomoo item covers the options chain, but no positioning data is provided.
Risk watch: The remaining items are generic market-wire coverage (flagged YELLOW). No specific risk events are identified in the source.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links or proprietary signals.

Open Questions

What are the reported revenue, operating income, net income, and free cash flow figures for the most recent quarters, given that the financials section is empty?
What do the recent earnings results (the 2026-10-23 Q2 release) show for growth and margin trends?
What is the analyst consensus rating and price target, and how do they compare with the current $14.11 price?
What is the institutional (13F) and insider (Form 4) ownership and activity pattern over recent quarters?
What is the company's revenue exposure by product, geography, and regulatory regime, and how sensitive is it to pricing pressure?

RDY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Dr. Reddy's Laboratories Ltd (RDY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RDY Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 17h ago

Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors

Yahoo Finance report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 20h ago

Dr. Reddy's Laboratories(RDY) Stock Options Chain | Quotes & News

Moomoo report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 23h ago

Dr. Reddy's Laboratories Limited 2027 Q2 - Results - Earnings Call Presentation (NYSE:RDY) 2026-10-23

Seeking Alpha report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 1d ago

Dr Reddy's Laboratories Ltd (RDY) Shares Surge 4.1% -- What GF S

GuruFocus report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Dr. Reddy's Laboratories Q2 Earnings Call Highlights

TradingView report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST MarketBeat • 1d ago

Dr. Reddy's Laboratories (NYSE:RDY) Stock Jumps 4.8% After Strong Earnings

MarketBeat report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Quiver Quantitative • 1d ago

Dr. Reddy's Laboratories (RDY) Stock Falls on Q2 2027 Earnings

Quiver Quantitative report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Fintel • 4d ago

Dr. Reddy's Laboratories Limited Announces USFDA Classifies FTO-SEZ Process Unit-02 Inspection as Voluntary Action Indicated

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RDY Bull vs. Bear Conversation Board — What's Your Call at $14.17?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RDY 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $15.24 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is RDY (C • RQD 64/100) a Buy at $14.11?

Welcome to the RDY (Dr. Reddy's Laboratories Ltd) Roar Pit. Current RQD Composite is 64/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.8x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $10.72 (-24.0%)

Spot @ $14.11

Pump the brakes on RDY — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on RDY, but look at what you are paying: 32.8x trailing P/E with tightening sector spreads. Unless Dr. Reddy's Laboratories Ltd expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $16.51 (+17.0%)

Spot @ $14.11

RDY cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on RDY, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $14.11 (52-wk range $11.36 - $15.67), any beat on forward guidance forces shorts and underweight funds to chase.